Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arbutus Biopharma Corporation (ABUS) on November 8 and set a price target of $6.50. The company’s shares closed on Friday at $4.65, close to its 52-week low of $4.01.
According to TipRanks.com, Nakae has 0 stars on 0-5 star ranking scale with an average return of -7.9% and a 31.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Research, Dicerna Pharma, and ProQR.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arbutus Biopharma Corporation with a $6.83 average price target.
See today’s analyst top recommended stocks >>
Based on Arbutus Biopharma Corporation’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $3.09 million. In comparison, last year the company had a GAAP net loss of $11.6 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
